Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm CTL019 in relapsed or refractory diffuse large B-cell lymphoma
NL-OMON55408Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2016
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tisagenlecleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Novartis. Primary endpoint: Overall response rate. Started Jul 2016; status: active, not recruiting.
02
Drugs
tisagenlecleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NL-OMON55408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55408.